2M BioTech (Claria Bioscience)

2M Biotech is a family office investment vehicle founded in 29 and based in Dallas Texas. The firm manages an evergreen structure and is looking to make equity investments into companies ranging from $.5 ? $5 million with a preference for the middle of that range. The firm is also willing to co-invest with investors they either know well or are able to get a strong reference for. The firm looks to invest in Seed and Series A rounds and looks to take a significant stake in the company?s equity. The firm prefers to invest in companies that are not located in an areas highly saturated with venture capital. The firm plans to make 3-4 new investments over the next 12 months.
Melissa Krauth
Principal 

AbbVie

AbbVie was founded by Abbott Laboratories in 213 and is based in Chicago IL. The firm partners with developmental-stage biotech companies and is actively seeking to in-license therapeutic assets. AbbVie generally seeks global rights to assets and will consider partnerships worldwide, the firm licenses assets opportunistically with no set rate of allocations. AbbVie also has a venture arm that makes equity investments AbbVie Venture & Early-Stage Collaborations.
Kevin Lynch
Vice President Search and Evaluation 

Addario Lung Cancer Medical Institute United States

The Addario Lung Cancer Medical Institute (ALCMI), founded in 2008 as a 501c(3) non-profit organization, is a patient-centric, international research consortium driving research otherwise not possible, evidenced by ALCMI's current clinical studies CASTLE, INHERIT EGFR T790M, Genomics of Young Lung Cancer and others. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 21+ institutions in the U.S., France, Italy, Spain and U.K., supported by dedicated research infrastructures such as centralized project management, tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through our network of community cancer centers – accelerating novel research advancements to lung cancer patients. 

Mr Steven Young
Mr Steven Young
LinkedIn logo President & COO 
BIO

Steven W. Young serves as the President & Chief Operating Officer of the Addario Lung Cancer Medical Institute, a patient-founded/-focused non-profit research consortium directly linking more than 20 academic and community centers via shared infrastructures (biorepository, data system) and centrally managed intramural translational projects in the United States, France, Italy and Spain.  After transitioning from the clinical research information technology industry, Mr. Young had played a central role in the development and evolution of the Multiple Myeloma Research Consortium as its Executive Director from 2003 through 2008.  Earlier still, he served as Director of the National Institutes of Health-funded General Clinical Research Center at Mount Sinai School of Medicine and the Pediatric Clinical Research Center at Cornell University College of Medicine, both in New York City.  Mr. Young resides in Weston, Connecticut with his wife and two sons.

Advax United States

AdVax is an inter/multi-disciplinary team of individuals who have developed major paradigm-shifting science, research, technology and new clinical data sets demonstrating previously unidentified bacterial infections are able to translocate to the brain and be linked to the induction of Alzheimer’s disease.

We have developed novel and proprietary real time molecular diagnostics to identify these non-culturable bacteria and then apply novel immune refocusing technologies to create both monoclonal antibodies that could be used in treatments and a first of its kind vaccine for the prevention of both cardiovascular and Alzheimer’s disease.

Our program is well on its way to identifying the major disease-inducing bacteria, which are then ready to be put into the immune refocusing technology for the derivation of human monoclonal antibodies and vaccines.

Dr Daniel Sindelar
Dr Daniel Sindelar
LinkedIn logo CEO 
BIO

Daniel L. Sindelar DMD attended business school at Saint Louis University and earned a dental degree at Washington University School of Dental Medicine in 1981. He is a practicing dentist and expert in oral systemic health. He is a co-founder and recent president of the American Academy for Oral Systemic Health (AAOSH). He has earned preceptorship certification by participating with cardiologists in the prevention of heart attack, stroke, and diabetes. He is the founder and director of Oral Genomics, LLC. A passionate advocate of oral-systemic health, he has developed online video educational systems for healthcare professionals.

Dr. Sindelar has been an instructor in the field of laser dentistry. He is the author of Refresh Life, a book on the importance of oral health on overall health and well-being and has been interviewed by local and national radio shows and print news outlets. He has written for various dental publications, lectured at major healthcare conferences, and has been featured in several cover stories in Dental Economics.

Advent Life Sciences United Kingdom

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

 

 


Dr Dale Pfost
Dr Dale Pfost
LinkedIn logo General Partner 

AFH Holding & Advisory

AFH Holding & Advisory LLC is a boutique investment banking firm that offers financial advisory services. The firm focuses on alternative public offerings marketing strategy planning capital structuring and mergers and acquisitions advisory. Its clientele include Carlisi Natural Gas Inc. Fossil Energy Group LLC Kaikai Technology Co. Ltd. and Yi Xin Copper Co. Ltd. AFH Holding & Advisory LLC is based in Beverly Hills California with an additional office in Pudong China.
Amir Heshmatpour
Founder & Managing Director 

Aisling Capital

Aisling Capital is a private equity group based in New York with over $1.6 billion in assets under management. Aisling is currently looking for new firms for potential investments for the firm?s third fund. The firm looks to make investments in companies seeking to raise a total round of $2-5 million. The firm looks to invest in companies globally with a focus on companies located in the United States.
Dennis Purcell
Founder and Senior Advisor 

Altravax United States

Altravax is a privately held biopharmaceutical company focused on developing first-in-class biological products to fight infectious diseases or treat other indications. The Company has a robust pipeline of candidates at various preclinical stages of development including a therapeutic vaccine against chronic hepatitis B infection. Altravax seeks investment opportunities to develop these lead candidates for clinical testing.

Website:
www.altravax.com
Year Founded
2009
Biotech Subsector
Biotech Phase of Development
Technology Overview
: Altravax’s proprietary Immunogen Optimization System™ (IOS) offers unique opportunities to create many types of novel biopharmaceutical product candidates with significantly improved safety, efficacy, manufacturability, stability, and toxicity for preclinical evaluation in a cost-effective manner.
Supporting Metrics or Evidence
A novel therapeutic hepatitis B vaccine containing improved antigen sequences has shown the abilities to induce superior antigen-specific B-cell and T-cell immune responses in animal experiments. The vaccine could potentially break immune tolerance, restore T-cell exhaustion, and have a significant therapeutic impact in chronic hepatitis B patients
Current Timeline
24-30 months to IND and 4 years to human POC with sufficient funding in place.
Current Investors
Arthur Ventures & an angel investor
IP Status
US and PCT filed.
Dr Sean Du
Co-Founder, Chief Operator Officer 

Apple Tree Partners United States

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Year Founded
1999
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sam Hall
Principal 
Aaron Kantoff
Vice President